Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors
31. Mai 2023 08:30 ET
|
Ashvattha Therapeutics
REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers...
Ashvattha Therapeutics Presents Preclinical Data on anti-VEGF Nanomedicine D-4517.2 at the 2023 ARVO Annual Meeting
26. April 2023 13:30 ET
|
Ashvattha Therapeutics
Data demonstrated that a single oral dose of D-4517.2 significantly reduced choroidal neovascularization (CNV) lesions to a level comparable to D-4517.2 delivered subcutaneously and Aflibercept...
Ashvattha Therapeutics Presented Promising Preclinical Data on Novel Macrophage Switching Nanomedicine D-4559 at AACR Annual Meeting
18. April 2023 09:00 ET
|
Ashvattha Therapeutics
Data demonstrated D-4559 switches tumor associated macrophages from an M2 to M1 pro-inflammatory phenotype leading to reduction in tumor growth in a mouse model of hepatocellular carcinomaThe data...
Ashvattha Therapeutics to Present Preclinical Data at the AACR and ARVO 2023 Annual Meetings
03. April 2023 08:30 ET
|
Ashvattha Therapeutics
Preclinical data to be presented at AACR will showcase the potential effect of D-4559, a potent macrophage switching nanomedicine, on reducing tumor growth in a mouse model of hepatocellular...
Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 1 Study of [18F]OP-801 for Use as Imaging Agent
06. Februar 2023 08:30 ET
|
Ashvattha Therapeutics
– The study will evaluate the safety, tolerability and ability of [18F]OP-801 to cross the blood brain barrier and selectively target neuroinflammation in individuals with ALS and healthy volunteers –...
Ashvattha Therapeutics to Present at Upcoming Investor Conferences
02. Februar 2023 08:30 ET
|
Ashvattha Therapeutics
REDWOOD CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a...
Ashvattha Therapeutics to Present at Biotech Showcase 2023
03. Januar 2023 08:30 ET
|
Ashvattha Therapeutics
REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a...
Ashvattha Therapeutics Announces the Appointment of Steve Maricich, M.D., Ph.D. as Chief Medical Officer
20. Oktober 2022 08:30 ET
|
Ashvattha Therapeutics
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics (HDTs), today announced that...
Ashvattha Therapeutics Announces Preclinical Data on Hydroxyl Dendrimer Based PET Tracer [18F]OP-801 Presented at the 2022 World Molecular Imaging Congress
29. September 2022 15:14 ET
|
Ashvattha Therapeutics
– Data demonstrated [18F]OP-801 is a promising tracer for imaging activated macrophages/microglia with high sensitivity in the lumbar spine of a murine model of multiple sclerosis (MS) – – Treatment...
Ashvattha Therapeutics Announces Presentations of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 World Molecular Imaging Congress (WMIC)
15. September 2022 08:00 ET
|
Ashvattha Therapeutics
– Scientific collaborators at Stanford University will present data on an imaging and treatment regimen demonstrating the microglial targeting of [18F]OP-801 in a mouse model of multiple sclerosis and...